Primecap Management Co. CA Sells 23,871 Shares of Repligen Co. (NASDAQ:RGEN)

Primecap Management Co. CA lowered its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 43.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,858 shares of the biotechnology company's stock after selling 23,871 shares during the quarter. Primecap Management Co. CA owned approximately 0.06% of Repligen worth $4,442,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of RGEN. Champlain Investment Partners LLC raised its stake in Repligen by 149.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company's stock valued at $211,464,000 after purchasing an additional 850,345 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Repligen during the fourth quarter valued at $52,492,000. Allspring Global Investments Holdings LLC raised its position in Repligen by 79.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company's stock valued at $65,395,000 after buying an additional 203,011 shares during the period. DF Dent & Co. Inc. lifted its stake in Repligen by 31.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company's stock worth $87,852,000 after acquiring an additional 139,615 shares in the last quarter. Finally, Two Sigma Advisers LP boosted its position in Repligen by 421.9% during the 3rd quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company's stock worth $18,796,000 after acquiring an additional 102,100 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Remove Ads

Insider Activity

In other Repligen news, Director Margaret Pax bought 250 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now directly owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.20% of the stock is currently owned by company insiders.

Repligen Stock Performance

Shares of RGEN stock traded up $5.13 during trading on Monday, reaching $145.15. The company had a trading volume of 492,811 shares, compared to its average volume of 651,232. The firm's 50 day simple moving average is $156.18 and its two-hundred day simple moving average is $148.40. Repligen Co. has a one year low of $113.50 and a one year high of $198.00. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company has a market capitalization of $8.15 billion, a PE ratio of -284.61, a PEG ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Sell-side analysts forecast that Repligen Co. will post 1.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RGEN has been the topic of a number of research reports. Evercore ISI assumed coverage on Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 target price on the stock. Royal Bank of Canada upped their price objective on shares of Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research note on Friday, February 21st. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price for the company. StockNews.com downgraded shares of Repligen from a "hold" rating to a "sell" rating in a research note on Friday, February 21st. Finally, JPMorgan Chase & Co. increased their price objective on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $178.64.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.